Gilbertsville Scientist Part of Cancer Detection Study
GILBERTSVILLE PA – Dr. Carl Ascoli, chief science officer at Rockland Immunochemicals Inc. in Gilbertsville and Limerick, is a named co-author of a recently publicized study that proposes a new blood test for breast cancer. It could increase detection of the disease, according to EIN Presswire.
The test uses exosomes, the body’s own particles, to search for the presence of a genetic protein that has been discovered in breast cancer tumors. Research indicates the protein, called BP1, occurs in the tumors of 89 percent of African American women, and 57 percent of Caucasian women, the report said.
The research and resulting study was led by Dr. Patricia Berg, professor emeritus at The George Washington University Medical Center. It suggests the study team’s conclusions could assist in breast cancer “diagnosis, prognosis, prevention, and treatment development.”
Rockland Immunochemicals, established in 1962, describes itself as a “global biotechnology company manufacturing leading-edge tools for basic, applied, and clinical research in functional genomics, gene therapy, and drug discovery markets.” The EIN Presswire article about the study was published Friday (Aug. 13, 2021).
2014 photo from Google Picasa